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Process intensification by continuous operation has been successfully applied in the chemical industry, when 
batch processes matured several decades ago. Fully integrated upstream and downstream continuous 
processing has also shown great potential for increased productivity and reduced cost in biomanufacturing using 
mammalian cell culture. After a few decades of development, continuous or perfusion cell culture has 
demonstrated for manufacturing of labile proteins or low-titer processes. Due to significant challenges 
implementing fully integrated continuous biomanufacturing and the fact that fed-batch cell culture has not yet 
matured, fed-batch cell culture and batch chromatography steps are still predominant for stable protein 
manufacturing in the industry. In comparison to perfusion cell culture, continuous or semi-continuous 
downstream processing for stable monoclonal antibodies (mAbs) has developed within less than a decade. Due 
to a high titer, e.g., 8-10 g/L, already achieved via fed-batch cell culture, which challenges the processing 
capacity for batch downstream commercial manufacturing, the demand of continuous chromatography operation 
dramatically increases. Here, we present a case study developing a hybrid continuous upstream and 
downstream as our next generation process for production of a stable mAb. For upstream, we implemented N-1 
perfusion seed, which significantly increased the seeding density for fed-batch production. After media and 
process parameter optimization, the product titer for the intensified fed-batch process with high-seed increased 
more than 100% over the original fed-batch process. It should be noted that the original fed-batch process was 
optimized and used for clinical manufacturing at 1000-L scale. For next generation downstream, we developed 
multi-column chromatography for Protein A step, automated VI step and integrated pool-less polishing 
chromatography steps with increased productivity and reduction in resin requirement, buffer consumption and 
processing time. The next generation process with perfusion N-1 seed and continuous chromatography steps 
has been scaled up in 500-L bioreactor, and now has been demonstrated for full implementation in a GMP 
manufacturing facility at the 2000-L scale. We will present full set of data to compare the original optimized 
batch process at 1000-L scale and the next generation process at 2000-L scale for the stable mAb production 
using CHO cell culture. We believe that the hybrid continuous process is relatively easy to develop and 
implement in GMP manufacturing with significantly higher productivity than conventional fed-batch process for 
now, while the hybrid continuous process lays a good foundation for us to further develop and implement fully 
continuous upstream and downstream process in manufacturing with even higher productivity in future. 
 
